Phase I Trial of CCL21-Modified Dendritic Cells and Pembrolizumab in NSCLC: Enhancing Antitumor Immunity in PD-L1 Low Tumors

Abstract Background: The majority of NSCLC patients do not respond to single agent PD-1/PD-L1 inhibitors, in part due to the lack of cytolytic T cell infiltration at the tumor site. To improve the efficacy of checkpoint blockade, in situ vaccination ...